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Abstract
Purpose: Radiation therapy (RT) and nivolumab are standard therapies for a wide range of ad-
vanced and metastatic cancers, yet little is known about the toxicity profile of their combined treatment.
The rate of grade ≥3 toxicities from nivolumab monotherapy and radiation-only palliative treat-
ments has been reported at 10% to 18% and 0% to 26%, respectively. We reviewed our experience
to assess the acute toxicity profile of concurrent RT-nivolumab.
Methods and materials: A retrospective review of all consecutive patients from January 2015 to
May 2017 who received concurrent RT-nivolumab was conducted at 4 separate centers. Concur-
rent RT-nivolumab was defined as RT completed between 3 days prior to initial nivolumab infusion
and 28 days after the last nivolumab infusion.
Results: Of the 261 patients who received nivolumab, 46 (17.6%) had concurrent RT to 67 treat-
ment sites. The median follow-up was 3.3 months (interquartile range, 1.7-6.1 months) and the 1-year
overall survival rate was 22%. For the 11 of 46 patients (24%) who were alive at last analysis, the
median follow-up was 12.8 months (interquartile range, 8.3-14.9 months). The most common his-
tology, RT prescription, and treatment site were non-small cell lung cancer (23 of 46 patients; 50%),
30 Gy in 10 fractions (24 of 67 patients; 35.8%), and abdomen/pelvis (16 of 67 patients; 24%),
respectively. Four patients with melanoma had concurrent ipilimumab and were removed from the
final toxicity analysis of RT-nivolumab. Within 3 months of treatment with RT-nivolumab, 4 of 42
patients (9.5%) experienced grade 3 toxicity and 2 of these patients’ toxicities were attributed spe-
cifically to the addition of RT: grade 3 hearing loss after whole brain RT and grade 3 pancreatitis
after stereotactic body RT to the left adrenal gland. One death from transaminitis was attributed to
nivolumab alone because the RT field did not encompass the liver.
Conclusions: Concurrent RT-nivolumab did not appear to increase the toxicity profile from the
previously reported toxicity rates from nivolumab or radiation alone.
© 2018 The Author(s). Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Nivolumab is a monoclonal antibody against pro-
grammed death-1 (PD-1) that has resulted in improved
outcomes in patients with a wide range of advanced or meta-
static cancers, including melanoma, non-small cell lung,
head and neck, lymphoma, renal, urothelial, colorectal, and
hepatocellular cancers.1-8 Radiation therapy (RT) is also com-
monly used in this patient population, most often at lower
doses to palliate symptoms but also at higher doses using
stereotactic body radiation therapy (SBRT) to ablate
oligometastatic sites of disease. Furthermore, a growing
amount of preclinical and clinical data describe the synergy
between checkpoint inhibitor immunotherapy and RT across
a wide range of RT doses.9-12 This potential synergy may
also increase the risk of toxicity, but this has not been well
defined in the limited number of retrospective studies and
case reports that have previously sought to address this
issue.13-15
Nivolumab monotherapy results in a 10% to 18% risk
of grades 3 to 4 immune-related adverse events (ir-AEs)
such as diarrhea, nephritis, pneumonitis, hypophysitis, and
hepatitis.8,16,17 Grade 5 fatalities due to nivolumab, which
may include but are not limited to encephalitis, neutrope-
nia, pneumonitis, acute renal failure, or heart failure, are
uncommon and account for <1% of treated patients.1,8,17,18
Palliative radiation may be associated with a range of tox-
icities depending on the part of the body treated, but typically
the rate of grade ≥3 toxicity is often negligible or up to
26%.19-23
The goal of this retrospective study is to better charac-
terize the toxicities experienced by patients receiving
concurrent RT and nivolumab to determine if or when greater
caution may be appropriate when considering the use of
this relatively new combined modality therapy in patients.
Methods and materials
A retrospective review of all patients from January 2015
to May 2017 who received concurrent RT-nivolumab was
conducted at 4 separate centers at 2 separate institutions.
For the purpose of this study, concurrent RT-nivolumab was
defined as RT administered from 3 days prior to initial
nivolumab infusion through 28 days after the final nivolumab
infusion. This starting point was selected because preclini-
cal studies have shown that RT-induced changes in the tumor
microenvironment peak 3 days after the last dose of RT.11
The 28-day ending point was selected because nivolumab’s
half-life of 26.7 days would result in approximately 50%
of the drug remaining in the body 28 days after infusion.
Descriptive statistics were used to summarize patient de-
mographics, treatment details, response to therapy, and
toxicity. Most patients were seen weekly during their RT
and at 1 month follow-up. We also utilized the medical on-
cology notes because the patients were seen prior to each
nivolumab cycle. Duration of follow up was calculated from
completion date of RT to last follow-up or date of death.
Toxicities during and after RT were assessed using the
Common Terminology Criteria for Adverse Events version
4.0. Any symptoms that were present prior to RT or initial
nivolumab administration were not classified as a toxicity
from either treatment. Most patients had baseline fatigue,
so this was not isolated as a side effect for further analy-
sis. Grades 1 and 2 toxicities were also not reported because
this study focused on more pronounced side effects that
would more significantly affect a patient’s quality of life.
RT treatment plans were further evaluated in patients with
grades 3 to 5 toxicities to determine whether the toxici-
ties could be attributed to the addition of RT. If a given
toxicity could be attributed to an organ within the RT field
and the timing of the toxicity was either during RT or within
3 months of completing RT, the toxicity was attributed to
RT; otherwise, it was considered to be from nivolumab alone.
Results
A total of 261 patients received nivolumab in the evalu-
ated timeframe, of whom 127 (48.7%) also received RT,
which was given concurrently with nivolumab in 46 pa-
tients (17.6%). Some of these patients received more than
one 1 course of RT with nivolumab for a total of 67 dif-
ferent irradiated sites. Four patients with melanoma also
received concurrent ipilimumab and were removed from
the toxicity evaluation for RT-nivolumab alone. In all cases,
nivolumab was initiated after previous progression of disease
on other types of systemic therapy. Table 1 describes ad-
ditional patient and treatment characteristics.
The median follow-up was 3.3 months (interquartile
range, 1.7-6.1 months) and the 1-year overall survival rate
was 22%. The majority of patients received palliative ra-
diation and died due to progression of systemic disease.
For the 11 of 46 patients (24%) who were alive at last analy-
sis, the median follow-up was 12.8 months (interquartile
range, 8.3-14.9 months).
Table 2 describes the RT characteristics including timing
of RT-nivolumab, location of treatment, RT prescription,
and technique. In addition to external beam radiation, 4 pa-
tients also received spatially fractionated grid radiation
therapy, hyperthermia, or a combination of both.
Overall, 4 patients (9.5%) experienced grade 3 toxic-
ity. There were no grade 4 toxicities and one grade 5 toxicity
due to nivolumab-induced hepatitis. Two of the grade 3 tox-
icities (4.8%) were attributed to the use of RT. The treatment
and toxicity details of these patients are described in Table 3.
None of the other treatment site locations, including ex-
tremities, chest wall/axilla, or head and neck, had any
unexpected or severe side effects. Also, none of the pa-
tients developed a severe or unexpected rash in the treatment
field, a commonly reported generalized side effect of im-
munotherapy alone. Details of the 2 unexpected side effects
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from concurrent RT-nivolumab that developed in the RT
field are described.
One patient developed grade 3 hearing loss after whole
brain radiation therapy (WBRT). This patient had prior ste-
reotactic radiation surgery (SRS) to 6 brain metastases that
were treated at 20 to 22 Gy to the 50% isodose line, com-
pleted 4 months prior to WBRT (30 Gy in 10 fractions) and
prior to his first dose of nivolumab. Subsequently, the patient
had 4 cycles of nivolumab prior to WBRT. Although the
patient had some hearing loss prior to WBRT, he reported
significantly worsening hearing loss during the 2 months
after completing WBRT. The patient was noted to have otitis
media with effusion in both ears with resultant eusta-
chian tube dysfunction, and an audiogram confirmed
significant grade 3 hearing loss with hearing aids indi-
cated. A brain magnetic resonance imaging scan did not
reveal any other explanation for the hearing loss. None of
the prior SRS treatments compromised the cochlea or in-
ternal auditory meatus. Although there was no prior
audiogram available for comparison and chronic ear in-
fections are known to lead to permanent hearing loss, WBRT
was thought to be the cause of the rapid decline in hearing,
which is an extremely rare side effect of WBRT alone.
Another patient unexpectedly developed grade 3 pan-
creatitis after 20 cycles of nivolumab and concurrent SBRT
(33 Gy in 3 fractions) to a left adrenal mass.24 Pancreati-
tis is a rare side effect of nivolumab and has never been
reported after SBRT; therefore, the synergy of both treat-
ments and toxicity profiles could have resulted in this
toxicity. However, another patient in our analysis who had
concurrent nivolumab-ipilimumab and SBRT (39 Gy in 3
fractions) to a left adrenal mass did not develop any signs
of pancreatitis during follow up. The factors that led to the
acute and unexpected side effect in one patient and not the
other are not clear. None of the other patients who re-
ceived SBRT experienced unexpected side effects.
Of note, among the 4 patients who received concur-
rent ipilimumab-nivolumab and RT, 3 (75%) experienced
Table 1 Patient and treatment characteristics of concurrent
nivolumab and radiation
n = 46 %
Age, years








Head and neck 3 6.5
Melanoma 9 19.6















a Zero indicates nivolumab was started either during radiation or
within 3 days of completing radiation therapy.
Table 2 Concurrent radiation therapy characteristics per site
n = 67 %
Timing of concurrent RT and nivolumab
RT completed ≤3 days prior to initial nivolumab 4 6.0
RT completed by final nivolumab 41 61.2
RT completed <14 days post-final nivolumab 6 9.0
RT completed >14-28 days post-final nivolumab 16 23.9
Location of treatment
Abdomen/pelvis (including spine) 16 23.9
Brain 12 17.9
Extremity 12 17.9
Chest wall/axilla 11 16.4
Thorax (including spine) 10 14.9
Head/neck (including spine) 6 9.0
Technique
3-dimensional conformal RT 54 80.6
SBRT 6 9.0
SRS 3 4.5
3-dimensional + SFGRT 2 3.0
3-dimensional + SFGRT + hyperthermia 1 1.5
3-dimensional + hyperthermia 1 1.5
Total dose/fraction (Dose/fraction)
30 Gy/10 fractions (3 Gy)a 24 35.8
20 Gy/5 fractions (4 Gy)b 14 20.9
8 Gy/1 fractions (8 Gy) 11 16.4
20-50.4 Gy/10-28 fractions (1.8-2 Gy) 5 7.5
20-57.5 Gy/5-23 fractions ± 12-15 Gy
SFGRT ± hyperthermia
4 6.0
21-39 Gy/3 fractions (7-13 Gy; SBRT) 4 6.0
15-22 Gy/1 fraction (Cranial SRS) 3 4.5
30-45 Gy/5 fractions (6-9 Gy; SBRT) 2 3.0
RT, radiation therapy; SBRT, stereotactic body radiation therapy;
SFGRT, spatially fractionated grid radiation therapy; SRS, stereotac-
tic radiation surgery.
a Includes 36 Gy/12 fractions and incomplete treatments: 5 treat-
ments of 27 Gy/9 fractions; 1 treatment of 24 Gy/8 fractions, and 1
treatment of 9 Gy/3 fractions.
b Includes 1 incomplete treatment of 16 Gy/4 fractions.
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grade 3 or 4 toxicity, only 1 was also attributed to RT. One
patient who received cranial SRS developed grade 4
hypophysitis resulting in hyponatremia (Na = 118), but the
pituitary was far from the SRS volume and deemed to be
unlikely to be radiation induced.
Another patient developed grade 3 acute interstitial ne-
phritis 9 months after SBRT to the left adrenal gland, which
also was not considered to be induced by RT given the very
low kidney dose. However the third patient received 20 Gy
in 5 fractions to a central lung tumor and developed grade
3 pneumonitis, likely exacerbated by the combination of
RT-nivolumab-ipilimumab. These 4 patients were removed
from the toxicity analysis of RT-nivolumab because com-
bined checkpoint blockers are known to have a higher side
effect profile than monotherapy.25
Discussion
Although cytotoxic chemotherapy is often held during
palliative RT due to an increased rate of side effects without
improvement in outcomes, it is impractical to hold
nivolumab during palliative RT because nivolumab would
take approximately 160 days (6 half-lives) to clear the pa-
tient’s body.19-21,23 Thus, it is inevitable that a patient on
nivolumab who receives RT would receive concurrent
therapy. Fortunately, our findings suggest that the addi-
tion of RT to nivolumab is generally safe and did not
increase the rate of grade ≥3 toxicities previously re-
ported for nivolumab monotherapy.
Prior studies using nivolumab monotherapy reported rates
of grade 3 to 4 toxicities ranging from 10% to 18% and
grade 5 as very rare. In a pooled analysis of 4 melanoma
studies that included 576 patients, there were no grade 5
toxicities and a 10% rate of grade 3 to 4 treatment-related
AEs.16 A larger meta-analysis including 5353 patients from
9 randomized trials including either pembrolizumab or
nivolumab reported the absolute risk of grade 3 to 4 AEs
was 12.9%, and only 5 patients died in the nivolumab arms.17
More recently, a report on the phase 2 trial of nivolumab
in metastatic urothelial cancers (CheckMate 275) re-
ported an 18% (48 of 270) rate of grade 3 to 4 treatment-
related AEs, most commonly grade 3 fatigue and diarrhea.
Three patients (1%) died from toxicities related to treat-
ment (pneumonitis, acute respiratory failure, and
cardiovascular failure, respectively).
Prior retrospective studies have tried to define the tox-
icity of combined RT-immunotherapy; however, all had small
patient numbers, their definitions of concurrent therapy
varied, and some evaluated several immunotherapy drugs
that are known to have different toxicity profiles. Never-
theless, because there have not been many studies on
nivolumab-RT specifically, it is valuable to discuss studies
evaluating other checkpoint inhibitors and RT. At least 3
retrospective studies have assessed the safety of com-
bined RT-ipilimumab, all with small cohorts ranging from
22 to 44 patients, and concluded that the combination of
RT and ipilimumab was generally safe with no increased
rates of local or systemic ir-AEs and only 14% to 15% rates
of grade 3 to 4 toxicity.26-28
Another retrospective evaluation of 56 patients who had
RT within 14 days of a checkpoint blockade (cytotoxic
T-lymphocyte-associated protein 4 and/or PD-1) con-
cluded that the ir-AEs did not appear to be associated with
the particular site irradiated, and the authors specified that
the toxicity rates of PD-1 inhibitors (pembrolizumab or
nivolumab) were 4% for grade 3 to 4 and 0% for grade 5.13
In another retrospective report on 26 patients with 73 mela-
noma brain metastases treated with intracranial radiosurgery
within 6 months of receiving nivolumab, the authors con-
Table 3 Details of Grade ≥3 toxicities from concurrent nivolumab and radiation
Toxicity
grade
Toxicity description RT target
description
RT prescription Reirradiation Nivolumab
cycles prior
to toxicity
Probable cause of toxicity
5 Hepatitis Duodenum 41 Gy/16 fx (2.5 Gy) No 3 Nivolumab only; liver not in
RT field
3 Pneumonitis; transaminitis L4-Sacrum 30 Gy/10 fx (3 Gy) No 2 Nivolumab only; neither
lungs nor liver in RT field
3 Enterocolitis T7-T9 30 Gy/10 fx (3 Gy) No 4 Nivolumab only; bowels not
in RT field
3 Sensorineural hearing loss Whole brain 30 Gy/10 fx (3 Gy) Yes, prior
cranial SRS
8 Combined RT-nivolumab;
extremely rare for hearing
loss from WBRT or
nivolumab alone
3 Pancreatitis Left adrenal
gland
33 Gy/3 fx (11 Gy) No 20 Combined RT-nivolumab;
extremely rare for
pancreatitis from SBRT or
nivolumab alone
fx, fraction; RT, radiation therapy; SBRT, stereotactic radiation therapy; SRS, stereotactic radiation surgery; WBRT, whole brain radiation therapy.
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cluded that the radiosurgery was well tolerated with only
2 patients developing grade 3 edema in the setting of con-
current intracranial metastatic progression. There were no
grade 4 or 5 toxicities reported.15
Lastly, there was another recent case report of concur-
rent nivolumab with 20 Gy in 4 fractions delivered to a large
cervix tumor. The treatment was well tolerated without any
significant toxicities and the patient had an excellent re-
sponse both locally and at distant areas of disease.14 All of
these studies concluded that the combination of palliative
RT and checkpoint inhibitors was well tolerated, with a 4%
to 14% rate of grade 3 to 4 toxicity and no deaths.
There are limitations of our study that are inherent to
its retrospective design. We did not have a control cohort
or predefined list of toxicities to report on, so certain sub-
clinical endocrinopathies or abnormal laboratory findings
may not have been identified or reported. It is difficult to
compare our toxicity rates to those from previous studies
that had different criteria or levels of surveillance for
toxicities.
We did not report on any corticosteroid use prior to or
during RT in our cohort. The use of steroids could have
altered the toxicity profile. Also, although our cohort of 42
patients who received RT-nivolumab is similar to the number
of patients in prior retrospective studies evaluating toxic-
ity of combination RT-immunotherapy, the small sample
size limits the power of statistical analysis to evaluate po-
tential risk factors for increased toxicity such as higher RT
doses, more cycles of nivolumab prior to RT, or treatment
site/lymphoid-rich tissues.
These limitations should be weighed against the strengths
of our study. Most notably, this was a multi-institutional
study and the largest study to describe toxicity among pa-
tients treated with concurrent nivolumab and RT. We also
used a strict time interval to define concurrent treatment
and had access to the RT plans to further evaluate the RT
field in relation to the toxicity. These strengths helped us
eliminate confounders of added toxicities from other im-
munotherapies and isolate and study patients who were in
an ideal window for RT-nivolumab synergy.
Although the toxicity did not always correlate to organs
within the RT field, local inflammatory response from RT
could trigger an abscopal inflammatory response leading to
toxicities in other organs of the body. Only a larger, prospec-
tive trial could shed light on this possibility of abscopal toxicity.
Until these studies are complete, oncologists must closely
monitor patients on RT-nivolumab as well as nivolumab
monotherapy and have a low threshold to initiate corticoste-
roids that can alleviate some ir-AEs and permit patients to
maximize the therapeutic benefit from immunotherapy.
Conclusions
This study did not detect an increase in grade ≥3 tox-
icity when RT was added to nivolumab compared with
nivolumab monotherapy or historical standards for pallia-
tive RT. These data are encouraging, but caution and further
understanding of combined RT and nivolumab, as well as
RT combined with other immunotherapies, are still needed.
Our experience adds to the emerging understanding of the
complex interactions of nivolumab and RT and helps guide
radiation oncologists when faced with a patient on nivolumab
who may benefit from RT for local control or palliation.
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